Envestnet Portfolio Solutions Inc. Sells 2,774 Shares of Cencora, Inc. $COR

Envestnet Portfolio Solutions Inc. lessened its stake in Cencora, Inc. (NYSE:COR) by 33.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,595 shares of the company’s stock after selling 2,774 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Cencora were worth $1,749,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Atlas Legacy Advisors LLC raised its stake in shares of Cencora by 11.2% in the third quarter. Atlas Legacy Advisors LLC now owns 4,677 shares of the company’s stock valued at $1,462,000 after buying an additional 470 shares during the period. BIP Wealth LLC raised its position in shares of Cencora by 11.6% in the third quarter. BIP Wealth LLC now owns 790 shares of the company’s stock worth $247,000 after buying an additional 82 shares in the last quarter. Triad Wealth Partners LLC boosted its position in shares of Cencora by 6.3% during the 3rd quarter. Triad Wealth Partners LLC now owns 2,323 shares of the company’s stock valued at $726,000 after acquiring an additional 138 shares during the last quarter. Rakuten Investment Management Inc. bought a new stake in Cencora during the third quarter valued at approximately $17,327,000. Finally, Cornerstone Wealth Group LLC grew its position in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after acquiring an additional 30 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on COR shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Mizuho upped their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Finally, JPMorgan Chase & Co. raised their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.08.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Shares of COR opened at $355.31 on Tuesday. Cencora, Inc. has a 52 week low of $237.71 and a 52 week high of $377.54. The stock has a market cap of $68.93 billion, a price-to-earnings ratio of 44.69, a PEG ratio of 1.68 and a beta of 0.66. The business has a 50-day simple moving average of $348.29 and a two-hundred day simple moving average of $322.63. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the prior year, the business posted $3.34 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.